MX2023004802A - Compuestos espiro heterocíclicos y métodos de uso. - Google Patents
Compuestos espiro heterocíclicos y métodos de uso.Info
- Publication number
- MX2023004802A MX2023004802A MX2023004802A MX2023004802A MX2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- spiro compounds
- heterocyclic spiro
- compounds
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020123913 | 2020-10-27 | ||
| PCT/US2021/056702 WO2022093856A1 (en) | 2020-10-27 | 2021-10-26 | Heterocyclic spiro compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004802A true MX2023004802A (es) | 2023-06-22 |
Family
ID=78650109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004802A MX2023004802A (es) | 2020-10-27 | 2021-10-26 | Compuestos espiro heterocíclicos y métodos de uso. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230406860A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4237086A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7860103B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021370660A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3199082A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004802A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022093856A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| CA3227138A1 (en) | 2021-07-23 | 2023-01-26 | Theras, Inc. | Compositions and methods for inhibition of ras |
| AR128211A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| AR128212A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| CN117186107A (zh) * | 2022-05-31 | 2023-12-08 | 成都先导药物开发股份有限公司 | 一种制备2-取代-5,7-二羰基-2,6-二氮杂螺[3,4]辛烷中间体的方法 |
| AU2023377064A1 (en) | 2022-11-09 | 2025-05-22 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| TW202615038A (zh) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物 |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080540A1 (es) | 2006-08-10 | 2008-06-08 | Glaxo Group Ltd | Compuestos 4-fenil-2-piridinil-metil sustituidos como moduladores de los canales de sodio con apertura por voltaje |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| AU2016245864C1 (en) * | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| BR112021001709A2 (pt) * | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| EP3887373A1 (en) | 2018-11-29 | 2021-10-06 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| AU2019404576B2 (en) | 2018-12-20 | 2025-07-17 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| MA54550A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| WO2020146613A1 (en) * | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
-
2021
- 2021-10-26 WO PCT/US2021/056702 patent/WO2022093856A1/en not_active Ceased
- 2021-10-26 CA CA3199082A patent/CA3199082A1/en active Pending
- 2021-10-26 MX MX2023004802A patent/MX2023004802A/es unknown
- 2021-10-26 US US18/033,439 patent/US20230406860A1/en active Pending
- 2021-10-26 AU AU2021370660A patent/AU2021370660A1/en active Pending
- 2021-10-26 EP EP21810231.7A patent/EP4237086A1/en active Pending
- 2021-10-26 JP JP2023524901A patent/JP7860103B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230406860A1 (en) | 2023-12-21 |
| AU2021370660A1 (en) | 2023-06-08 |
| JP2023549055A (ja) | 2023-11-22 |
| CA3199082A1 (en) | 2022-05-05 |
| WO2022093856A1 (en) | 2022-05-05 |
| EP4237086A1 (en) | 2023-09-06 |
| JP7860103B2 (ja) | 2026-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025004108A (es) | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos | |
| MX2025004109A (es) | Inhibidores heterocíclicos de las proteínas mutantes kras g12c y utilizaciones de los mismos | |
| MX2025013001A (es) | Inhibidores espiro-heterocíclicos de las proteínas mutantes kras g12c y usos de los mismos. | |
| MX2025013504A (es) | Inhibidores de kras de anillo fundido para el tratamiento de enfermedades | |
| MX2022015739A (es) | Inhibidores alostericos de egfr y metodos de uso de estos. | |
| SA521422405B1 (ar) | Mat2a مثبطات أزا-غير متجانسة ثنائية الحلقة لـ وطرق الاستخدام لعلاج السرطان | |
| JOP20210317A1 (ar) | مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| PH12021551493A1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| WO2019191470A8 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| GEP20247710B (en) | Small molecule inhibitors of kras g12c mutant | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MX2021004624A (es) | Derivados de 2-(2-acriloil-2,6-diazaspiro[3.4]octan-6-il)-6-(1h-in dazol-4-il)-benzonitrilo y compuestos relacionados como inhibidores de la proteina kras mutante g12c para inhibir metastasis de tumor. | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| AU2020281332A8 (en) | Dna-dependent protein kinase inhibitor | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| EA201691142A1 (ru) | Ингибиторы мек и способы их применения | |
| ZA202304734B (en) | Alpha protein kinase 1 inhibitors and methods of use | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
| MX2025014397A (es) | Inhibidores de helicasa de adn recq del sindrome de werner (wrn) | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. |